Skip to Content

Guaifenesin / Hydrocodone / Pseudoephedrine Dosage

Medically reviewed on August 25, 2017.

Applies to the following strengths: 200 mg-2.5 mg-30 mg/5 mL; 200 mg-5 mg-60 mg/5 mL; 100 mg-2.5 mg-30 mg/5 mL; 300 mg-5 mg-30 mg; 100 mg-2.5 mg-15 mg/5 mL; 100 mg-3 mg-15 mg/5 mL; 200 mg-6 mg-45 mg/5 mL; 50 mg-3.75 mg-22.5 mg/5 mL

Usual Adult Dose for Cough and Nasal Congestion

10 mL orally every 4 to 6 hours
Maximum dose: 40 mL in 24 hours

-Each 5 mL contains hydrocodone 2.5 mg; pseudoephedrine 30 mg; guaifenesin 200 mg
-Measure dose with accurate measuring device.

Use: Symptomatic relief of cough, nasal congestion, and to loosen mucus associated with the common cold.

Renal Dose Adjustments

Severe renal impairment: Use with caution

Liver Dose Adjustments

Severe hepatic impairment: Use with caution

Dose Adjustments

Elderly: Use with caution


-Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule II


Data not available

Other Comments

Administration advice:
-Take orally as needed
-Measure each dose with an accurate measuring device; a household teaspoon is not an accurate measuring device

Storage requirements:
-Protect from light

-This drug is not indicated for pediatric patients under 18 years of age; use of hydrocodone in children less than 6 years of age has been associated with fatal respiratory depression.

-Monitor for the development of addiction, abuse, or misuse

Patient advice:
-Advise patients to store this drug safely out of the sight and reach of children; accidental use by a child should be considered a medical emergency as it can result in death.
-Patients should understand the risks of life-threatening respiratory depression, and should be informed as to when this risk is greatest.
-Women of child bearing potential should understand that prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome and prompt recognition and treatment will be necessary; breastfeeding women should speak to their health care provider prior to using this drug.
-Patients should discuss concomitant medication use with their healthcare provider to prevent significant drug interactions.
-Patients should not consume alcoholic beverages or take this drug with benzodiazepines or other CNS depressants; patients should avoid driving or operating machinery while taking this drug.
-Patients should be instructed in proper disposal.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.